Last reviewed · How we verify

E. Coli Cervicitis — Treatment Landscape & Competitive Intelligence

E. Coli Cervicitis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating E. Coli Cervicitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Fortaz CEFTAZIDIME Pai Holdings Pharm ceftazidime 1985-01-01
Ceftazidim Ceftazidim Tel-Aviv Sourasky Medical Center Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pai Holdings Pharm · 2 drugs in E. Coli Cervicitis
  2. Tel-Aviv Sourasky Medical Center · 1 drug in E. Coli Cervicitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in E. Coli Cervicitis:

Cite this brief

Drug Landscape (2026). E. Coli Cervicitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-cervicitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing